Status:
COMPLETED
Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites
Lead Sponsor:
Tang-Du Hospital
Conditions:
Refractory Ascites
Eligibility:
All Genders
18+ years
Brief Summary
Currently, there is limited evidence regarding the survival benefit of early transjugular intrahepatic portal shunt (TIPS) placement in patients with cirrhosis and recurrent ascites. This observationa...
Eligibility Criteria
Inclusion
- Definite diagnosis of recurrent ascites in cirrhosis (based on clinical symptoms, laboratory and imaging studies, or liver biopsy) TIPS or LVP+A therapy, -
Exclusion
- Malignant neoplasm, including hepatocellular carcinoma with extrahepatic metastasis Prior liver transplantation Severe heart and lung dysfunction Recurrent hepatic encephalopathy Concomitant active infection TIPS with the use of uncovered stents Complete portal vein thrombosis
- \-
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT06196723
Start Date
December 1 2023
End Date
February 1 2024
Last Update
August 27 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Tangdu hospital
Xi'an, Shaanxi, China, 710000
2
Xi'an International Medical Center Hospital
Xi'an, Shaanxi, China, 710000
3
Xijing hospital
Xi'an, Shaanxi, China, 710000